Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs Evogliptin for Liver Fibrosis in CHB and T2DM
NCT05473806Phase 4Unknown
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Liver Fibrosis (LF) comparing Pioglitazone Arm with Evogliptin Arm (2 arms). Primary endpoint: Liver Stiffness Measurement at 24 weeks. Status: unknown.
02
Drugs
pioglitazoneDA5221-B2
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05473806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473806.